Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 23;16(9):1623.
doi: 10.3390/cancers16091623.

Axillary Surgery for Breast Cancer in 2024

Martin Heidinger  1   2 , Walter P Weber  1   2
Affiliations
Review

Axillary Surgery for Breast Cancer in 2024

Martin Heidinger et al. Cancers (Basel). .

Abstract

Axillary surgery for patients with breast cancer (BC) in 2024 is becoming increasingly specific, moving away from the previous 'one size fits all' radical approach. The goal is to spare morbidity whilst maintaining oncologic safety. In the upfront surgery setting, a first landmark randomized controlled trial (RCT) on the omission of any surgical axillary staging in patients with unremarkable clinical examination and axillary ultrasound showed non-inferiority to sentinel lymph node (SLN) biopsy (SLNB). The study population consisted of 87.8% postmenopausal patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative BC. Patients with clinically node-negative breast cancer and up to two positive SLNs can safely be spared axillary dissection (ALND) even in the context of mastectomy or extranodal extension. In patients enrolled in the TAXIS trial, adjuvant systemic treatment was shown to be similar with or without ALND despite the loss of staging information. After neoadjuvant chemotherapy (NACT), targeted lymph node removal with or without SLNB showed a lower false-negative rate to determine nodal pathological complete response (pCR) compared to SLNB alone. However, oncologic outcomes do not appear to differ in patients with nodal pCR determined by either one of the two concepts, according to a recently published global, retrospective, real-world study. Real-world studies generally have a lower level of evidence than RCTs, but they are feasible quickly and with a large sample size. Another global real-world study provides evidence that even patients with residual isolated tumor cells can be safely spared from ALND. In general, few indications for ALND remain. Three randomized controlled trials are ongoing for patients with clinically node-positive BC in the upfront surgery setting and residual disease after NACT. Pending the results of these trials, ALND remains indicated in these patients.

Keywords: axillary lymph node dissection; axillary surgery; breast cancer; sentinel lymph node biopsy; tailored axillary surgery.

PubMed Disclaimer

Conflict of interest statement

Walter P. Weber received research support from Agendia paid to the University Hospital Basel and honoraria for lectures from MSD. Martin Heidinger has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Accrual of the TAXIS study.
See this image and copyright information in PMC

References

    1. Fisher B. The Surgical Dilemma in the Primary Therapy of Invasive Breast Cancer: A Critical Appraisal. Curr. Probl. Surg. 1970;7:3–53. doi: 10.1016/S0011-3840(70)80007-7. - DOI - PubMed
    1. Fisher B. Laboratory and Clinical Research in Breast Cancer—A Personal Adventure: The David A. Karnofsky Memorial Lecture. Cancer Res. 1980;40:3863–3874. - PubMed
    1. Fisher B., Redmond C., Fisher E.R., Bauer M., Wolmark N., Wickerham D.L., Deutsch M., Montague E., Margolese R., Foster R. Ten-Year Results of a Randomized Clinical Trial Comparing Radical Mastectomy and Total Mastectomy with or without Radiation. N. Engl. J. Med. 1985;312:674–681. doi: 10.1056/NEJM198503143121102. - DOI - PubMed
    1. Louis-Sylvestre C., Clough K., Asselain B., Vilcoq J.R., Salmon R.J., Campana F., Fourquet A. Axillary Treatment in Conservative Management of Operable Breast Cancer: Dissection or Radiotherapy? Results of a Randomized Study with 15 Years of Follow-Up. J. Clin. Oncol. 2004;22:97–101. doi: 10.1200/JCO.2004.12.108. - DOI - PubMed
    1. Veronesi U., Paganelli G., Viale G., Luini A., Zurrida S., Galimberti V., Intra M., Veronesi P., Robertson C., Maisonneuve P., et al. A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer. N. Engl. J. Med. 2003;349:546–553. doi: 10.1056/NEJMoa012782. - DOI - PubMed